9.60
-0.17 (-1.74%)
| Penutupan Terdahulu | 9.77 |
| Buka | 9.70 |
| Jumlah Dagangan | 841,353 |
| Purata Dagangan (3B) | 906,653 |
| Modal Pasaran | 1,322,112,000 |
| Harga / Jualan (P/S) | 16.14 |
| Harga / Buku (P/B) | 0.820 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -9,184.54% |
| EPS Cair (TTM) | -3.93 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -9.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.09% |
| Nisbah Semasa (MRQ) | 8.94 |
| Aliran Tunai Operasi (OCF TTM) | -466.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -356.99 M |
| Pulangan Atas Aset (ROA TTM) | -19.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Vir Biotechnology, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.50 |
|
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.90% |
| % Dimiliki oleh Institusi | 74.36% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bill & Melinda Gates Foundation | 30 Jun 2024 | 1,559,142 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (HC Wainwright & Co., 1,045.83%) | Beli |
| Median | 26.00 (170.83%) | |
| Rendah | 19.00 (Needham, 97.92%) | Beli |
| Purata | 51.67 (438.23%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 7.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Nov 2024 | 110.00 (1,045.83%) | Beli | 6.74 |
| 04 Nov 2024 | 110.00 (1,045.83%) | Beli | 9.37 | |
| Needham | 20 Nov 2024 | 19.00 (97.92%) | Beli | 6.74 |
| 01 Nov 2024 | 19.00 (97.92%) | Beli | 9.26 | |
| Barclays | 04 Nov 2024 | 26.00 (170.83%) | Beli | 9.37 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |